This study explores the therapeutic potential of an agonistic antibody targeting dendritic cell immunoreceptor (DCIR) in modulating immune responses. The research investigates how engaging DCIR with a specific antibody can inhibit ITAM-mediated inflammatory signaling pathways, thereby promoting the resolution of inflammation.
Treatment with the agonistic anti-DCIR antibody effectively inhibited ITAM-mediated signaling, leading to reduced pro-inflammatory cytokine production and enhanced immune resolution. These findings suggest that targeting DCIR could be a viable strategy for treating inflammatory and autoimmune diseases.
The study utilized a genetically engineered mouse model developed in collaboration with genOway. This model features a humanized version of the DCIR gene (CLEC4A), replacing the murine counterpart, allowing for the assessment of human-specific antibody interactions and their immunomodulatory effects in vivo.
Inflammatory diseases, Autoimmunity, Immunotherapy, Monoclonal antibody treatment, Immune regulation
Humanized gene replacement, Transgenic mouse model, Immune receptor targeting, In vivo antibody efficacy, Human-mouse chimeric model
From model design to experimental results
Tailor-made solutions adapted to scientific questions
Comprehensive dataset package
Generated with biopharma partners and in-house
Scientific follow-up and advice along the project
Collaborative approach for problem solving and development of innovative models
Breeding facilities in US and Europe
Certified health status from professional breeders
